Amgen Announces Voting Results of Annual Meeting of Stockholders
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 7, 2008--Amgen
(NASDAQ:AMGN), today announced results of voting at the company's
Annual Meeting of Stockholders, held at the Four Seasons Hotel
Westlake Village in Westlake Village, Calif. Approximately 86.9
percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Jerry
D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer,
Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D.
Schaeffer and Kevin W. Sharer were each reelected to Amgen's Board of
Directors, each receiving a majority of 'For' votes of the votes cast
and each was elected by no less than 87.7 percent of the votes cast.
With the reelection of these directors, Amgen currently has 11
With approximately 97.6 percent of 'For' votes of the votes cast,
stockholders ratified Ernst & Young as Amgen's independent registered
public accountants for the year ending Dec. 31, 2008.
Stockholders approved a nonbinding resolution recommending that
the company eliminate the supermajority voting requirements in its
bylaws and certificate of incorporation. The proposal received
approximately 78.7 percent of votes cast 'For' the proposal.
Stockholders rejected a proposal relating to animal welfare. The
proposal received less than 4.9 percent of the votes cast 'For' the
The final vote totals will be included in the company's next
quarterly report to be filed with the Securities and Exchange
Amgen discovers, develops, manufactures and delivers innovative
human therapeutics. A biotechnology pioneer since 1980, Amgen was one
of the first companies to realize the new science's promise by
bringing safe and effective medicines from lab, to manufacturing
plant, to patient. Amgen therapeutics have changed the practice of
medicine, helping millions of people around the world in the fight
against cancer, kidney disease, rheumatoid arthritis and other serious
illnesses. With a deep and broad pipeline of potential new medicines,
Amgen remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk: 805-447-4613 (media)
Arvind Sood: 805-447-1060 (investors)